

Inventor: Steward et al.
Serial No.: 09/942,098
Filed: August 28, 2001
Page 2

CURRENT STATUS OF CLAIMS WITH CLAIM AMENDMENTS

1. **(Original)** A clostridial toxin substrate, comprising:

- (a) a donor fluorophore;
- (b) an acceptor having an absorbance spectrum overlapping the emission spectrum of said donor fluorophore; and
- (c) a clostridial toxin recognition sequence comprising a cleavage site,

wherein said cleavage site intervenes between said donor fluorophore and said acceptor and wherein, under the appropriate conditions, resonance energy transfer is exhibited between said donor fluorophore and said acceptor.

2. **(Original)** The substrate of claim 1, comprising a botulinum toxin recognition sequence.

3. **(Original)** The substrate of claim 2, provided that said botulinum toxin recognition sequence is not a botulinum toxin serotype B (BoNT/B) recognition sequence.

4. **(Original)** A botulinum toxin serotype A (BoNT/A) substrate, comprising:

- (a) a donor fluorophore;
- (b) an acceptor having an absorbance spectrum overlapping the emission spectrum of said donor fluorophore; and
- (c) a BoNT/A recognition sequence comprising a cleavage site,

Inventor: Steward et al.
Serial No.: 09/942,098
Filed: August 28, 2001
Page 3

wherein said cleavage site intervenes between said donor fluorophore and said acceptor and wherein, under the appropriate conditions, resonance energy transfer is exhibited between said donor fluorophore and said acceptor.

5. **(Original)** The substrate of claim 4, comprising at least six consecutive residues of SNAP-25, said six consecutive residues comprising Gln-Arg, or a peptidomimetic thereof.

6. **(Currently amended)** The substrate of claim 5, comprising at least six consecutive residues of a human SNAP-25, said six consecutive residues comprising Gln197-Arg198, or a peptidomimetic thereof.

7. **(Original)** The substrate of claim 6, comprising the amino acid sequence Glu-Ala-Asn-Gln-Arg-Ala-Thr-Lys (SEQ ID NO: 1), or a peptidomimetic thereof.

8. **(Original)** The substrate of claim 6, comprising residues 187 to 203 of human SNAP-25 (SEQ ID NO: 2), or a peptidomimetic thereof.

Claims 9-44 (cancelled)

45. **(Currently amended)** The substrate of any of claims 1, 2, 3 or 4 ~~1, 2, 3, 4, 9, 14, 21, 26, 31, 36 or 40~~, wherein said substrate can be cleaved with an activity of at least 1 nanomole/minute/milligram toxin ~~nanomoles/minute/milligram toxin~~.

Inventor: Steward et al.
Serial No.: 09/942,098
Filed: August 28, 2001
Page 4

46. **(Currently amended)** The substrate of any of claims 1, 2, 3 or 4 1, 2, 3, 4, 9, 14, 21, 26, 31, 36 or 40, wherein said substrate can be cleaved with an activity of at least 20 nanomole/minute/milligram toxin nanomoles/minute/milligram toxin.

47. **(Currently amended)** The substrate of any of claims 1, 2, 3 or 4 1, 2, 3, 4, 9, 14, 21, 26, 31, 36 or 40, wherein said substrate can be cleaved with an activity of at least 50 nanomole/minute/milligram toxin nanomoles/minute/milligram toxin.

48. **(Currently amended)** The substrate of any of claims 1, 2, 3 or 4 1, 2, 3, 4, 9, 14, 21, 26, 31, 36 or 40, wherein said substrate can be cleaved with an activity of at least 100 nanomole/minute/milligram toxin nanomoles/minute/milligram toxin.

49. **(Currently amended)** The substrate of any of claims 1, 2, 3 or 4 1, 2, 3, 4, 9, 14, 21, 26, 31, 36 or 40, wherein said substrate can be cleaved with an activity of at least 150 nanomole/minute/milligram toxin nanomoles/minute/milligram toxin.

50. **(Original)** The substrate of claim 1, wherein said acceptor is an acceptor fluorophore.

51. **(Original)** The substrate of claim 50, wherein said acceptor fluorophore has a fluorescent lifetime of at least 1 microsecond.

Inventor: Steward et al.
Serial No.: 09/942,098
Filed: August 28, 2001
Page 5

52. **(Original)** The substrate of claim 1, wherein said acceptor is non-fluorescent.

53. **(Original)** The substrate of claim 1, wherein said donor fluorophore is fluorescein.

54. **(Canceled)**

55. **(Original)** The substrate of claim 1, wherein said donor fluorophore is DABCYL.

56. **(Canceled)**

57. **(Original)** The substrate of claim 1, claim 53, or claim 54, wherein said acceptor is tetramethylrhodamine.

58. **(Original)** The substrate of claim 1 or claim 55, wherein said acceptor is EDANS.

59. **(Currently amended)** The substrate of claim 1, claim 53 or claim 54, wherein said acceptor is [QSY® 7] a non-fluorescent acceptor.

60. **(Original)** The substrate of claim 1, which is a peptide or peptidomimetic having at most 100 residues.

61. **(Original)** The substrate of claim 60, which is a peptide or peptidomimetic having at most 50 residues.

62. **(Original)** The substrate of claim 61, which is a peptide or peptidomimetic having at most 40 residues.

Inventor: Steward et al.
Serial No.: 09/942,098
Filed: August 28, 2001
Page 6

63. **(Original)** The substrate of claim 62, which is a peptide or peptidomimetic having at most 20 residues.

64. **(Currently amended)** The substrate of claim 50 [[1]], wherein said donor fluorophore and said acceptor fluorophore are separated by at most fifteen residues.

65. **(Original)** The substrate of claim 64, wherein said donor fluorophore and said acceptor fluorophore are separated by at most ten residues.

66. **(Original)** The substrate of claim 65, wherein said donor fluorophore and said acceptor fluorophore are separated by at most eight residues.

67. **(Original)** The substrate of claim 66, wherein said donor fluorophore and said acceptor fluorophore are separated by at most six residues.

Claims 68-95 (cancelled)